GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » FS Development Corp II (NAS:FSII) » Definitions » Loans Receivable

Switch to:

FS Development II (FS Development II) Loans Receivable : $0.00 Mil (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is FS Development II Loans Receivable?

FS Development II's Loans Receivable for the quarter that ended in . 20 was $0.00 Mil.

FS Development II Loans Receivable Historical Data

The historical data trend for FS Development II's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FS Development II Loans Receivable Chart

FS Development II Annual Data

Trend

Dec20

Loans Receivable

-

FS Development II Semi-Annual Data
	Dec20
Loans Receivable	-

FS Development II Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

FS Development II Loans Receivable Related Terms

Thank you for viewing the detailed overview of FS Development II's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

FS Development II (FS Development II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » FS Development Corp II (NAS:FSII) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Montgomery Street, Suite 4500, San Francisco, CA, USA, 94111

Website

FS Development Corp II is a blank check company.

FS Development II (FS Development II) Headlines

From GuruFocus

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

By Business Wire Business Wire • 12-21-2021

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

By Marketwired Marketwired • 08-05-2021

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

By Business Wire Business Wire • 12-01-2021

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

By GuruFocusNews GuruFocusNews • 12-27-2021

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

By Marketwired Marketwired • 08-26-2021

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

By Business Wire Business Wire • 06-29-2021

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.